266 related articles for article (PubMed ID: 20828379)
21. Downregulation of Xeroderma Pigmentosum Complementation Group C Expression by 17-Allylamino-17-Demethoxygeldanamycin Enhances Bevacizumab-Induced Cytotoxicity in Human Lung Cancer Cells.
Chen JC; Ko JC; Taso YC; Cheng HH; Chen TY; Yen TC; Lin YW
Pharmacology; 2021; 106(3-4):154-168. PubMed ID: 33202406
[TBL] [Abstract][Full Text] [Related]
22. Geldanamycin and its analog induce cytotoxicity in cultured human retinal pigment epithelial cells.
Wu WC; Wu MH; Chang YC; Hsieh MC; Wu HJ; Cheng KC; Lai YH; Kao YH
Exp Eye Res; 2010 Aug; 91(2):211-9. PubMed ID: 20493187
[TBL] [Abstract][Full Text] [Related]
23. Heat shock protein 90 inhibition abrogates hepatocellular cancer growth through cdc2-mediated G2/M cell cycle arrest and apoptosis.
Watanabe G; Behrns KE; Kim JS; Kim RD
Cancer Chemother Pharmacol; 2009 Aug; 64(3):433-43. PubMed ID: 19082595
[TBL] [Abstract][Full Text] [Related]
24. SNX-2112, a novel Hsp90 inhibitor, induces G2/M cell cycle arrest and apoptosis in MCF-7 cells.
Wang SX; Ju HQ; Liu KS; Zhang JX; Wang X; Xiang YF; Wang R; Liu JY; Liu QY; Xia M; Xing GW; Liu Z; Wang YF
Biosci Biotechnol Biochem; 2011; 75(8):1540-5. PubMed ID: 21821931
[TBL] [Abstract][Full Text] [Related]
25. Regulation of the EGFR Pathway by HSP90 Is Involved in the Pathogenesis of Cushing's Disease.
Shen Y; Ji C; Jian X; Zhou J; Zhang Q; Qiao N; Zhang Y; Shou X; Zhou X; Ma Z
Front Endocrinol (Lausanne); 2020; 11():601984. PubMed ID: 33537004
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of constitutive and cxc-chemokine-induced NF-kappaB activity potentiates ansamycin-based HSP90-inhibitor cytotoxicity in castrate-resistant prostate cancer cells.
Seaton A; Maxwell PJ; Hill A; Gallagher R; Pettigrew J; Wilson RH; Waugh DJ
Br J Cancer; 2009 Nov; 101(9):1620-9. PubMed ID: 19809428
[TBL] [Abstract][Full Text] [Related]
27. The heat shock protein 90 inhibitor 17-AAG suppresses growth and induces apoptosis in human cholangiocarcinoma cells.
Zhang J; Zheng Z; Zhao Y; Zhang T; Gu X; Yang W
Clin Exp Med; 2013 Nov; 13(4):323-8. PubMed ID: 22955701
[TBL] [Abstract][Full Text] [Related]
28. Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
Holmes JL; Sharp SY; Hobbs S; Workman P
Cancer Res; 2008 Feb; 68(4):1188-97. PubMed ID: 18281495
[TBL] [Abstract][Full Text] [Related]
29. Heat Shock Protein 90 Inhibitor (17-AAG) Induces Apoptosis and Decreases Cell Migration/Motility of Keloid Fibroblasts.
Yun IS; Lee MH; Rah DK; Lew DH; Park JC; Lee WJ
Plast Reconstr Surg; 2015 Jul; 136(1):44e-53e. PubMed ID: 26111331
[TBL] [Abstract][Full Text] [Related]
30. In vitro study comparing the efficacy of the water-soluble HSP90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non‑water-soluble HSP90 inhibitor, 17-AAG, in breast cancer cell lines.
Ghadban T; Jessen A; Reeh M; Dibbern JL; Mahner S; Mueller V; Wellner UF; Güngör C; Izbicki JR; Vashist YK
Int J Mol Med; 2016 Oct; 38(4):1296-302. PubMed ID: 27498942
[TBL] [Abstract][Full Text] [Related]
31. The effects of Hsp90 expression alteration on spinal metastases of breast carcinoma.
Yan W; Xiao J; Liu T; Huang W; Yang X; Wu Z; Huang Q; Qian M
Tumour Biol; 2013 Jun; 34(3):1391-7. PubMed ID: 23456764
[TBL] [Abstract][Full Text] [Related]
32. The HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin modulates radiosensitivity by downregulating serine/threonine kinase 38 via Sp1 inhibition.
Enomoto A; Fukasawa T; Takamatsu N; Ito M; Morita A; Hosoi Y; Miyagawa K
Eur J Cancer; 2013 Nov; 49(16):3547-58. PubMed ID: 23886587
[TBL] [Abstract][Full Text] [Related]
33. Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation.
Krishnamoorthy GP; Guida T; Alfano L; Avilla E; Santoro M; Carlomagno F; Melillo RM
J Biol Chem; 2013 Jun; 288(24):17481-94. PubMed ID: 23629654
[TBL] [Abstract][Full Text] [Related]
34. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases.
Yao Q; Nishiuchi R; Li Q; Kumar AR; Hudson WA; Kersey JH
Clin Cancer Res; 2003 Oct; 9(12):4483-93. PubMed ID: 14555522
[TBL] [Abstract][Full Text] [Related]
35. Effects of 17-AAG on the cell cycle and apoptosis of H446 cells and the associated mechanisms.
Zhao X; Wang J; Xiao L; Xu Q; Zhao E; Zheng X; Zheng H; Zhao S; Ding S
Mol Med Rep; 2016 Aug; 14(2):1067-74. PubMed ID: 27279418
[TBL] [Abstract][Full Text] [Related]
36. The role of heat shock protein 90 in migration and proliferation of vascular smooth muscle cells in the development of atherosclerosis.
Kim J; Jang SW; Park E; Oh M; Park S; Ko J
J Mol Cell Cardiol; 2014 Jul; 72():157-67. PubMed ID: 24650873
[TBL] [Abstract][Full Text] [Related]
37. Protection of murine neural progenitor cells by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin in the low nanomolar concentration range.
Wang G; Krishnamurthy K; Tangpisuthipongsa D
J Neurochem; 2011 May; 117(4):703-11. PubMed ID: 21395580
[TBL] [Abstract][Full Text] [Related]
38. Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth.
Lang SA; Moser C; Gaumann A; Klein D; Glockzin G; Popp FC; Dahlke MH; Piso P; Schlitt HJ; Geissler EK; Stoeltzing O
Clin Cancer Res; 2007 Nov; 13(21):6459-68. PubMed ID: 17975158
[TBL] [Abstract][Full Text] [Related]
39. Hsp90 modulates human sperm capacitation via the Erk1/2 and p38 MAPK signaling pathways.
Sun P; Wang Y; Gao T; Li K; Zheng D; Liu A; Ni Y
Reprod Biol Endocrinol; 2021 Mar; 19(1):39. PubMed ID: 33663544
[TBL] [Abstract][Full Text] [Related]
40. Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin.
Wu X; Wanders A; Wardega P; Tinge B; Gedda L; Bergstrom S; Sooman L; Gullbo J; Bergqvist M; Hesselius P; Lennartsson J; Ekman S
Br J Cancer; 2009 Jan; 100(2):334-43. PubMed ID: 19142186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
